Related references
Note: Only part of the references are listed.Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA
Olivier Fitoussi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
Catherine Thieblemont et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Christian Recher et al.
LANCET (2011)
Prevention of CNS relapse in diffuse large B-cell lymphoma
Robert Kridel et al.
LANCET ONCOLOGY (2011)
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
Frederic Peyrade et al.
LANCET ONCOLOGY (2011)
Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated With a Low Risk of CNS Recurrence in High-Risk Patients With Diffuse Large B-Cell Lymphoma
Jeremy S. Abramson et al.
CANCER (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study
Umberto Vitolo et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
Andres J. M. Ferreri et al.
LANCET (2009)
Germinal center or nongerminal center DLBCL?
Gerhard Held et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Primary mediastinal large B-cell lymphoma
Maurizio Martelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support:: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
C. Tarella et al.
LEUKEMIA (2007)
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
T. El Gnaoui et al.
ANNALS OF ONCOLOGY (2007)
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients:: A study by the Groupe d'Etude des Lymphomes de I'Adulte
Christophe Bonnet et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma
Elizabeth C. Moser et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
F Reyes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
SM Horwitz et al.
BLOOD (2004)
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
T Kewalramani et al.
BLOOD (2004)
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
H Tilly et al.
BLOOD (2003)
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group
E Zucca et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)